Outcomes in Pretreated, Refractory Multiple Myeloma Remain Poor

Share this content:
Outcomes for patients with heavily pretreated or highly refractory multiple myeloma remain poor, despite the availability of newer agents.
Outcomes for patients with heavily pretreated or highly refractory multiple myeloma remain poor, despite the availability of newer agents.

Outcomes for patients with heavily pretreated or highly refractory multiple myeloma remain poor, despite the availability of newer agents, according to a study published in The Oncologist.1

In a retrospective study, researchers evaluated the electronic health records of 500 and 162 patients with multiple myeloma through the IMS LifeLink and OPTUM databases, respectively, who were refractory to both a proteasome inhibitor and an immunomodulatory drug, and who showed disease progression within 60 days of their most recent regimen.

The researchers observed similar median overall survival for eligible patients in both the IMS LifeLink and OPTUM databases.

RELATED: Marizomib Promising for Patients With Recurrent or Refractory Multiple Myeloma

Upon subgroup analyses of the IMS LIfeLink data set, median overall survival was found to be longer in patients who were younger than 65 years of age, than for those who were at least 65 years of age at eligibility. The same was true among patients with good or unreported performance status at last claim, compared to those with poor performance status.

Reference

  1. Usmani S, Ahmadi T, Ng Y, et al. Analysis of real-world data on overall survival in multiple myeloma patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016 Aug 2. doi: 10.1634/theoncologist.2016-0104 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs